TP53 and endometrial cancer: Here, we showed the independent prognostic value of the four molecular subgroups—POLE-mutated, MMR-deficient, p53-abnormal, ‘no specific molecular profile’ (NSMP)—on a cohort of high-risk endometrial cancer patients.